Pharmacogenetics and Age-Related Macular Degeneration

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td align="left">Treatment</td><td align="center">Genes</td><td align="left">Result</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td align="left">AREDS vitamins</td><td align="center"><i>CFH</i> and <i>ARMS2 </i></td><td align="left"><i>CFH </i>TT associated with greater reduction in disease progression; no effect with <i>ARMS2</i> [<a href="/journals/joph/2011/252549/#B53">53</a>]</td></tr><tr><td align="left">IVTA</td><td align="center">Multiple</td><td align="left">No association between IOP elevation and any gene [<a href="/journals/joph/2011/252549/#B72">54</a>]</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>AREDS: Age-Related Eye Disease Study; IOP: intraocular pressure; IVTA: intravitreal triamcinolone acetonide.<br/></td></tr></table>

Pharmacogenetics of AREDS vitamins and intravitreal triamcinolone acetonide.

Journal of Ophthalmology

tab1

Table 1

Table 1: Pharmacogenetics and Age-Related Macular Degeneration 